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Abstract.  We have studied the expression of the hu- 
man SRY protein (termed p27SRY)  in two different 
cell lines by using specific antibodies. Confocal mi- 
croscopy enabled us to localize p27SRY precisely in 
the nucleus in a discrete punctuate pattern. Further- 
more, through microinjection experiments, we have 
demonstrated that the localization of the p27SRY pro- 
tein into the nucleus was an event involving the NH2- 
terminal part of the high mobility group (HMG) do- 
main. With the help of several synthetic peptides and 
various p27SRY mutants, we have characterized a 
bipartite basic motif in this part of the protein corre- 
sponding to a  nuclear localization signal. This nuclear 
localization signal appears to be highly conserved in 
SRY box- and HMB box-containing proteins,  suggest- 
ing common properties of nuclear targeting within the 
HMG box protein family. 
I 
N mammals, the presence or absence ofa Y chromosome 
is known to correlate with male or female phenotype. 
In the absence of the Y chromosome, undifferentiated 
gonads (fetal genital ridges) develop as ovaries, while in its 
presence they will develop as testes. It is therefore believed 
that a genetic switch named testis determining factor (TDF) ~ 
and localized on the Y chromosome diverts the primordial 
gonads from the ovarian pathway towards male differentia- 
tion to form testes. In human, this event takes place at about 
six weeks of embryonic life. Given that Sertoli cells are the 
first testicular cell type to differentiate (Jost et al., 1981), the 
genetic switch is believed to commit a specific cell lineage 
to the  Sertoli  cell  differentiation pathway,  which  is then 
responsible for the production of the anti-Miillerian hor- 
mone (AMH also known as Miillerian inhibiting substance 
or MIS) (Josso et al.,  1993). 
Using  sex-reversed  patients,  a  single  Y-located  gene, 
termed sex determining region Y chromosome (SRY) in hu- 
man and Sry in mice, has recently been identified and cloned 
(Sinclair et al.,  1990;  Gubbay et al.,  1990).  Growing evi- 
dence supports SRY identity with TDF: first, de novo muta- 
tions affecting  the human SRY open reading frame are present 
in some 46, XY females with complete gonadal dysgenesis 
Address all correspondence to P. Berta, Centre de Recherche de Biochimie 
Macromoleculaire CNRS/INSERM, 1919 route de Mende BP 5051-34033 
Montpellier Cedex, France. Tel.: (33) 67-61-33-23.  Fax: (33) 67-52-15-19. 
1. Abbreviations  used in this paper:  HMG, high mobility group; NLS, nu- 
clear localization signal; p27SRY, human SRY gene encoded protein; RT- 
PCR, reverse transcription-polymerase chain reaction; SOX protein, SRY 
box containing protein; SRY, sex determining region Y chromosome; TDF, 
testis determining factor. 
(Berta et al., 1990; Jiiger et al., 1990). Next, the murine ho- 
mologue Sry was shown to be expressed in the normal de- 
veloping embryo in the genital ridges from 10.5-12.5-d post- 
coitum just prior to the differentiation of the genital ridges 
into testes (Koopman et al., 1990). Finally, addition of a 14- 
kb DNA fragment derived from mouse Y chromosome and 
including the Sry gene, induced transgenic mice with a XX 
chromosomal background to develop as phenotypic males 
(Koopman et al., 1991). However, the mode of action of the 
SRY gene product remains puzzling. A predominant feature 
of the SRY protein is a 79-amino acid motif referred to as 
the high mobility group (HMG) box, a conserved domain in 
many DNA-binding proteins including several transcription 
factors (Ner,  1992).  This led to the proposition that SRY 
could be a DNA-binding protein. Thus, by analogy it could 
play the role of a transcriptional regulator of downstream 
genes involved in the sex-determining pathway. Preliminary 
results confirmed this assumption: using either the SRY open 
reading frame or the potential DNA-binding motif in gel 
shift experiments, the ability of SRY protein to bind DNA 
in a sequence-specific manner was demonstrated (Harley et 
al., 1991; Nasrin et al., 1991; Denny et al., 1992). The spec- 
ificity of the binding was assessed by the demonstration that 
sex-reversed  females with point mutations in the SRY gene, 
as described in approximately 15 % of XY females (Berta et 
al., 1990; Hawkins et al., 1992), lose part or all of this bind- 
ing activity (Harley et al.,  1992; Poulat et al.,  1994).  Fur- 
thermore, like other members of the high mobility group 
family of DNA-binding proteins, SRY has been shown to in- 
teract with DNA double helix in the minor groove (Van de 
Wetering and Clevers, 1992) inducing a substantial bend in 
target DNA (Giese et al.,  1992;  Ferrari et al.,  1992).  Fi- 
nally,  SRY  protein  binds  with high affinity to  cruciform 
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1992). 
In this study, we describe the production and characteriza- 
tion of an antibody directed against the human testis deter- 
mining SRY gene product (also termed p27SRY). Using this 
specific antibody, we provide information about the nuclear 
localization of the p27SRY protein in human cells expressing 
the endogenous SRY gene. The nuclear localization signal of 
the p27SRY protein has been defined following microinjec- 
tion of several SRY-derived peptides and p27SRY mutant ex- 
pression plasmids. 
Materials and Methods 
Construction of  p27SRY Protein Expression Plasmid, 
Production of  p27SRY Protein 
For p27SRY expression in mammalian cells, DNA encoding the SRY open 
reading frame (Sinclair et al., 1990) was subcloned into the pJ3fl expression 
vector (in which the DNA sequence of interest is under control of a SV-40 
promoter) (Morgenstern and Land, 1990). A HinelI fragment isolated from 
the SRY containing clone pY53.3 (Sinclair et al., 1990) was ligated into the 
pJ31~ vector previously cut with Sma I  (GIBCO-BRL, Erangy, France). 
This construction was termed pJ3SRY. Mutant forms of SRY gene were pro- 
duced using the Transformer Mutagenesis Kit (Clontech, Ozyme, France). 
For p27SRY expression in bacteria, DNA encoding the SRY open read- 
ing frame was PCR amplified and subcloned in the pOTSV bacterial expres- 
sion vector system (Schatzman et al., 1987) at the BamHI/XhoI sites. The 
resulting plasmid was used to transform the AR58 bacterial strain as previ- 
ously described (Schatzman et al.,  1987).  Cells were grown at 300C  and 
induced at 42"C for 90 min. After purification, inclusion bodies were solu- 
bilized in Laemmli buffer (40 mM Tris-HCl, pH 6.8, 1% SDS, 50 mM DTT, 
7.5%  glycerol). 
Peptide Synthesis 
Peptides were produced using continuous flow solid-phase synthesis essen- 
tially as described previously (Poulat et al.,  1992),  and purified by semi- 
preparative RP-HPLC. Sequences were then shown to be correct by amino 
acid analysis and the purity was further checked by HPLC and HPCE. 
SRY80 peptide corresponds to the entire SRY box motif (Sinclair et al., 
1990)  and  SRY64  to  the  same  sequence lacking  the  16  NH2-terminal 
residues. SRY21 refers to the potential nuclear localization sequence from 
the SRY DNA binding motif, in sequence DRVKRPMNAFIVWSRDQR- 
RKMC corresponding to amino acids 58 to 78 of human p27SRY. SRY17 
corresponds to amino acids 40 to 56 (CNSKYQCETGENSKGNV) of the 
p27SRY  protein NH2-terminal region. Peptide SV40  (KKKRKVC) corre- 
sponds to the strong NLS of the large T antigen from the SV- 40 simian 
virus.  All  peptides were coupled to  rabbit lgG  (Sigma,  France)  using 
m-maleydobenzoyI-N-hydroxysulfosuccinimide ester  (Pierce,  Interchim, 
France). Peptide-protein conjugates were filtered on PD10 column (Phar- 
macia, France) equilibrated in PBS. 
Antibody Production and Purification 
Synthetic peptide (SRY17) was coupled to thyroglobulin (Sigma, France) 
or to BSA (Sigma) as described before. Male New Zealand rabbits were in- 
jected with 300 #g of thyroglobulin peptide conjugate mixed with complete 
Freund's adjuvant (Sigma). Rabbits were injected every two weeks with 100 
t~g of  the same protein preparation in incomplete Freund's adjuvant (Sigma), 
and bled  10 days after each injection. Polyclonal antisera were purified 
using a BSA-peptide conjugate coupled to CNBr Sepharose (Pharmacia, 
France) as previously described (Girard et al., 1991) and will be further re- 
ferred to as Y127.3 antibody. 
Western Blotting 
Nuclei were prepared as follows: cells were washed with cold PBS, col- 
lected with a rubber policeman and lysed with a Dounce homogenizer in 
0.5%  NP-40,  10  mM  Tris-HC1,  pH  7.4,  10  mM  NaCI,  3  mM  MgCI2 
buffer.  Nuclei were purified by centrifugation (3,000  g, 8 rain, 4°C) on a 
sucrose cushion (30% sucrose, 50 mM Tris-HCI, pH 8.3, 5 mM MgC12, 
0.1 mM EDTA),  and then lysed in Laemmli buffer, and sonicated for 20 s. 
Inclusion bodies containing the p27SRY recombinant protein were solubi- 
lized in the same buffer.  All samples were boiled for 5 min, separated on 
12.5%  SDS-PAGE and transferred to nitrocellulose. Nitrocellulose sheets 
were saturated in 8% nonfat dried milk in 25 mM Tris HCI, pH 7.5, 200 
mM NaCI (TBS) for I h, and then incubated with anti-SRY antibody (conc. 
0.3 mg/ml) diluted 1:100 in TBS for 1 h at room temperature. After exten- 
sive washing in TBS containing 0.05 % Tween 20 and  1 h resaturation in 
8%  milk,  horseradish  peroxidase conjugated  to  anti-rabbit  antibodies 
(Amersham) was added at 1:10,000 for 1 h. Detection of the immune signal 
was carried out by using the ECL detection system (Amersham). 
For competition experiments, 7 #g of Y127.3 were allowed to react with 
peptides SRY17 or SRY21 in a final volume of  200 ~1 for I h at room temper- 
ature, and then diluted to 1:100 in TBS and used for Western blotting as 
described above. 
Cell Culture 
NT2DI  cells (N-Tera  2, clone D1, a human pluripotent embryonic carci- 
noma cell line, ATCC No. CRL 1973) were obtained from the American 
Type Culture Collection (ATCC,  Biovaley, France), HS68 cells (a human 
adult fibroblastic cell line, ECACC No. 89051701) and HeLa cells (a human 
cervix carcinoma cell line, ECACC No. 85060701)  were obtained from the 
European  collection of animal  cell  culture  (ECACC,  Sophia-antipolis, 
France). NT2D1 cells, HeLa cells and human HS68 or H8 fibroblasts were 
cultured in DME (Imperial Laboratories, Flobio, France) containing 10% 
(vol/vol) FCS (GIBCO-BRL), penicillin/streptomycin, and 2  mM gluta- 
mine as described (Girard et al.,  1992).  For microinjection experiments, 
cells were plated onto acid washed glass coverslips essentially as described 
previously (Fernandez et at., 1991) and used 2-3 d after subculture. Human 
embryonic fibroblasts H8 were obtained from a 2 mm  3 skin fragment of a 
8-wk human male embryo obtained after voluntary abortion. Cells were 
serially passaged every 3 d essentially as described by Todaro and Green 
(1963).  After 33  passages, cells were subjected to limit dilution and in- 
dividual clones 10-23 grown up for use. 
Establishment of  a p27SRY Expressing HeLa Cell  Line 
To obtain a reference cell line, we established a p27SRY protein expressing 
stable transfectant. Since HeLa cells cannot express the SRY gene product 
because they do not contain a Y chromosome, we cotransfected this cell line 
with pJ3SRY vector and pcDNA Neo (Clontech, Ozyme, France) to estab- 
lish a stable transfectant for the human SRY gene. Briefly, 5  ×  10  s HeLa 
cells were transfected with both plasmids for one night at  37°C  using 
Lipofectine reagent (GIBCO-BRL). Cells were then washed, diluted, and 
incubated for 2 wk in the presence of 500/zg Neomycin (GIBCO-BRL) per 
ml of 10% FCS DME. Cell clones were then collected, amplified, and ana- 
lyzed for SRY gene expression using reverse transcription followed by poly 
merase chain reaction (RT- PCR) experiments. Positive and negative clones 
were then analyzed for p27SRY protein expression using immunoblotting 
experiments as previously described. A p27SRY expressing clone was next 
selected and termed "HeLa SRYB3Y 
Embryonic Tissue  Preparation 
8-wk-old male or female fetuses were obtained from therapeutic termina- 
tion (weeks of gestation). Sections of unfixed frozen tissues (10-/zm thick) 
were cut on a cryostat at -25°C. Sections were placed onto coated polyly- 
sine slides, dried for 1 h at room temperature, and then wrapped in cling 
film and stored at -20°C. Prior to immunolocalization, wrapped sections 
were fixed with -20°C methanol for 5 rain, and rehydrated in PBS. Sections 
were probed using the Y127.3 antibody and then processed as described be- 
low. DNA visualization was obtained using Hoechst 33286  staining. 
Microinjection and Immunofluorescence 
Cells growing on glass coverslips were microinjected with plasmid DNA 
essentially as follows. After allowing the cells to grow, selected areas were 
demarked on the coverslips by removing surrounding cells with fine forceps. 
After transferring the coverslips to prewarmed (37°C) PBS (to prevent the 
salts in DME from precipitating DNA), the nuclei of cells were injected 
by  introducing the  needle into the center of the nuclei,  withdrawing it 
slightly to prevent nuclear material from blocking the needle point, and ap- 
plying pressure.  10-50 cells were routinely injected per experiment. For 
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of cells essentially  as described previously  (Fernandez et al.,  1991). 
All injection solutions routinely contained an inert mouse IgG antibody 
(Sigma)  to enable subsequent identification  of injected cells.  Cells were 
fixed at different periods following injection (12-15 h for plasmid injected 
cells and 0-30 rain for IgG coupled peptide injections)  in 3.7% formalin 
in PBS at 25°C for 4 rain. Following extraction in -200C acetone and re- 
hydration  in PBS-BSA (0.1% BSA in PBS) cells were stained with Y127.3 
antibody for the distribution of p27SRY protein or with biotinylated anti- 
rabbit (Amersham) for the distribution of rabbit IgG coupled peptides (both 
diluted  1/100 in PBS-BSA). Cells were simultaneously stained for the inert 
marker antibody using fluorescein-conjugated  anti-mouse antibody (Capel, 
Organon Technika,  France) (diluted 1/40). After washing in PBS, primary 
antibodies were visualized with biotinytated  anti-rabbit  (dilution 1/400) and 
Texas red-conjugated streptavidin (dilution  1/1,000) for the detection of 
p27SRY and with Texas red-conjugated streptavidin alone to visualize rab- 
bit IgG-coupled peptides. After washing in PBS, cells were mounted in Air- 
vol 205 as described before  (Girard et al.,  1991). 
For immunofluorescence  experiments  concerning p27SRY expressing 
cells (NT2D1 and H8.2),  the same protocol was used without fluorescein- 
conjugated anti-mouse antibody. 
Results 
Production of  a Specific Antibody against the SRY 
Protein and Characterization of Two SRY Expressing 
Cell Lines 
To examine the expression and cellular distribution of  the hu- 
man  SRY  gene product in mammalian  cells,  an antibody 
against a peptide derived from the sequence of the p27SRY 
protein  was  raised.  This  sequence  termed  SRY17  corre- 
sponds to amino acids 40 to 56 of the human p27SRY protein 
(Sinclair et al.,  1990). This sequence is excluded from the 
putative DNA binding domain of p27SRY and was chosen 
so as to minimize potential cross-reactivity with related pro- 
teins, the so-called SOX proteins ("SRY  bOX") (Griffiths, 
1991) which display an homologous HMG domain with the 
p27SRY protein. 
The specificity of the resulting affinity purified antibody 
Y127.3  was initially determined using Western blotting ex- 
periments. As shown in Fig.  1, Y127.3 detects a major pro- 
tein at around 27 kD in total cell lysates from bacteria in- 
duced to express recombinant p27SRY protein (Fig.  1, lane 
2). This molecular weight is in good agreement with the cal- 
culated  molecular weight deduced from the open reading 
frame of the SRY gene. By contrast, no signal was present 
in bacterial lysates lacking the p27SRY encoding plasmid 
(Fig.  1, lane 1 ) or from the nuclear extracts of two different 
cell lines: HS68, a human male adult fibroblast cell line (Fig. 
1,  lane 3) and HeLa, a  human cervix carcinoma cell line 
(Fig. 1, lane 4). However, Y127.3 did recognize a major 27- 
kD protein in nuclear extracts derived from HeLa cells trans- 
fected with human SRY gene under the regulation of the SV- 
40 promoter (HeLa SRYB3) (Fig.  1, lane 5).  In all cases, 
this 27-kD protein immunoreactivity was not present with 
the preimmune serum, and could be specifically abolished 
after preincubation of the Y127.3 antibody with either the 
immunizing  peptide  (SRY17)  or  purified p27SRY  protein 
(data not shown); in contrast, an irrelevant peptide (SRY21), 
was unable to abolish the Y127.3 immunoreactivity (data not 
shown). 
Endogenous  expression  of  the  p27SRY  protein  was 
screened  in  two  different cell  lines:  N-Tera  2  clone  D1 
(NT2D1), a pluripotent embryonic carcinoma cell line (An- 
Figure 1. Western blotting characterization of the human p27SRY 
protein.  Monospecific  oligoclonal  antibodies  (Y127.3) raised 
against a part of the amino terminal domain of p27SRY were used 
as a probe for p27SRY. Shown are (lane 1) bacteria with empty 
plasmid expression vector, (lane 2) bacteria  induced to express 
p27SRY protein, (lane 3) HS68 cell nuclear extract, (lane 4) Hela 
cell nuclear extract, (lane 5) SRY stably transfected Hela cell nu- 
clear extract (Hela SRYB3), (lane 6) NT2DI cell nuclear extract, 
(lane 7) Hg cell (passage 2) nuclear extract (termed H8.2), and 
(lane 8) H8 cell (passage 10) nuclear extract (termed H8.10). White 
arrows show the position at which p27SRY migrates. Proteins were 
run on a 12.5% polyacrylamide gel. The migration of the mol wt 
standards, trypsin inhibitor (20 kD), carbonic anhydrase (31 kD), 
ovalbumin (43 kD) and albumin (67 kD) have been marked on the 
nitrocellulose filter after Ponceau red staining and before immuno- 
staining. Molecular weights are given in kD. The estimated molec- 
ular weight of SRY protein is around 27 kD. 
drews et al., 1984), and H8, a human embryonic non trans- 
formed cell  line  developed in  our  laboratory.  Using  the 
Y127.3 antibody in Western blotting experiments, a protein 
of 27 kD was detected in NT2D1 nuclear extracts, in good 
agreement with the molecular weight ofp27SRY (Fig. 1, lane 
6). However, this immunoreactivity was only detectable in 
H8 nuclear extracts of cells from passage 1 to 9 (Fig. 1, lane 
7).  Expression of the Y127.3  immunoreactive protein de- 
creased rapidly with cellular passages, and completely dis- 
appeared after ten cell passages (Fig.  1, lane 8).  Interest- 
ingly  the  protein  detected  in  the  NT2D1  and  H8  cells 
migrated with the same molecular weight as the protein ex- 
pressed in the Hela B3 cells,  but in all three cases it was 
different when compared to the bacterially expressed pro- 
tein.  This  difference of electrophoretic mobility  between 
bacterially or cellularly expressed proteins could result from 
post-translational  modifications  of p27SRY  in  eukaryotic 
cells, since the human SRY transcript is encoded by a mono- 
exonic gene (Suet al.,  1993; Behlke et al.,  1993). Further- 
more, we have observed phosphorylation of p27SRY protein 
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count for these differences (Poulat, E, and P. Berta, manu- 
script in preparation). 
Tricoli and co-workers did not detect any SRY gene ex- 
pression in the original cell line NTera 2, using RT-PCR ex- 
periments (Tricoli et al., 1993). However  the subclone exam- 
ined  here  (clone  D1)  has  been  recently  described  to  be 
positive for the SRY transcript (Clepet et al.,  1993). 
Western blotting experiments using total cellular extracts 
were  also  performed.  In  this  case,  identification  of  the 
p27SRY protein was very difficult to obtain reproducibly, 
probably reflecting the low overall quantity of p27SRY pro- 
tein present in these cells. Furthermore, when Western blot- 
ting  experiments  were  carried  out  using  the  cytoplasmic 
fraction of the cellular extract, no significant immunoreac- 
tivity  with  the  antibody  Y127.3  was  detected  (data  not 
shown), suggesting that the p27SRY protein is essentially nu- 
clear. 
From these data, we can conclude that the 27-kD protein 
detected with the Y127.3  antibody in cellular extracts is in- 
deed the p27SRY protein encoded by the human SRY gene. 
Nuclear Localization  of  p27SRY Protein in NT2D1, 
H8, and Embryonal Cells 
To investigate the cellular localization of the p27SRY pro- 
tein, we examined a number of cell lines for the distribution 
of p27SRY using indirect immunofli~orescence with the help 
of the Y127.3 antibody characterized above. Cells were then 
examined by confocal scanning laser microscopy, with the 
confocal plane passing through the center of the cells.  As 
shown in Fig. 2, p27SRY staining appears essentially local- 
ized in the nucleus of the NT2D1 cells throughout all stages 
of interphase (Fig. 2, D and E). The low level of cytoplasmic 
staining which can be detected is similar in intensity to the 
background cytoplasmic staining observed with preimmune 
Figure 2. Two cell lines spontaneously expressing p27SRY protein show a discrete nuclear punctuated immunofluorescent staining. Asyn- 
chronously growing cells H8 and NT2D1 were fixed and processed for immunofluorescence using Y127.3 antibody. Using confocal micros- 
copy, H8 cells from passage 2 (A) and NT2D1 cells (D) display a nuclear staining made up of bright spots of inununofluorescence. When 
several cells are examined in the same field, the immunofiuorescent staining is heterogeneous in intensity between the cells. Some ceils 
show a very low level of p27SRY staining (white arrows, B: H8.2 cells culture and E: NT2DI cell culture), by contrast with bright staining 
visible in other ceils in the field. When the antibody Y127.3 was preincubated with the immune peptide (SRY17) prior to the immunofluores- 
cence experiments,  no staining was detectable  in each cell line (C and F). Bar, 5 #m. 
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plays  a  brightly  punctated  pattern  of immunofluorescent 
foci throughout the nucleus and could represent some impor- 
tant localized concentrations of p27SRY protein associated 
with chromatin. 
Similar  staining  was  also  observed  in  human  H8  em- 
bryonic fibroblasts across passages 1 to 9 (Fig. 2, A and B). 
This p27SRY  staining completely disappeared after 10 pas- 
sages  (data  not shown),  confirming the previous Western 
blotting experiments. 
In these two cell lines, the level of immunoreactivity with 
Y127.3  is  not homogeneous as  proved by the  staining  of 
different cells in the same micrographic field (Fig. 2, B and 
E):  some cells display a  strong Y127.3  staining,  whereas 
others show very low if any immunoreactivity (Fig. 2, B and 
E, white arrows). Although the reasons for this are presently 
unclear, it could result of the use of asynchronously growing 
cell culture. This observation could not be explained by a 
heterogeneity of the cellular population since both NT2D1 
and  H8  cell  lines  were  derived  from  a  single  clone. 
Moreover, NT2D1 cells were cultured at high density to pre- 
vent heterogeneous differentiation as recommended by the 
purchaser. 
High  resolution  optical  sectioning  revealed  that  the 
p27SRY staining was always excluded from the nucleoli in 
the two cell lines (Fig. 3, A and C), as confirmed by phase 
contrast micrography (Fig.  3, B and D). 
To confirm this nuclear localization, a preincubation of the 
affinity purified antibody with peptide SRY17 was carried 
out. As shown in Fig. 2 (C and F), this preincubation com- 
pletely  abolished  the  nuclear  staining  in  both  cell  lines, 
strongly suggesting that the nuclear staining within the nu- 
cleus of NT2DI and H8 cells represents the true localization 
of p27SRY protein in these two cell lines. Secondly, the ab- 
sence of p27SRY expression in H8 cells after the tenth pas- 
sage,  as detected using  Western blotting experiments was 
confirmed by the absence of immunofluorescence staining in 
the same cells (data not shown). 
Finally, the immunolocalization of the SRY protein and its 
punctated pattern as observed in these two cell lines were 
confirmed using gonadal tissue from four 8-wk-old male fe- 
tuses (Fig. 4). Furthermore, this staining was also shown to 
be absent in a female embryo (Fig. 4, E). However, although 
the protein was always punctated and nuclear, we did ob- 
serve differential levels of staining in different areas of the 
section. Since the present analysis included less than 50 sec- 
Figure 3. p27SRY is excluded 
from  the  nucleoli.  Nuclei 
from H8.2 and  NT2D1 cells 
were observed using confocal 
microscope. (A and C) H8.2 
and NT2D1 cell nuclei where 
the  p27SRY staining  is  ex- 
cluded from the nucleoli (grey 
arrows). (B and D) Phase con- 
trast micrographs of the H8.2 
and NT2D1 cells nuclei show- 
ing  the  nucleoli  (white  ar- 
rows).  Bar, 5 /zm. 
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expressed  in the gonadal tis- 
sue of  a male fetus is localized 
within  the  nucleus  with  a 
punctate immunostaining  pat- 
tern.  10-/xm-thick  sections 
from  male  and  female  em- 
bryos  were  immunostained 
with  Y127.3 anti-SRY  anti- 
body and  Hoechst 33286  to 
visualize  DNA, as described 
in  Materials  and  Methods. 
Only  the  gonadal  region  is 
shown in each panel.  (A and 
B) lmmunofluorescence  stain- 
ing with  Y127.3 revealed  the 
nuclear  localization  of  SRY 
gene product in only a subset 
of  cells in the gonad. Shown in 
B is the DNA staining  of the 
same ceils.  (C and D) Higher 
magnification reveal the punc- 
tate  immunolocalization  of 
the SRY gene product in the 
nuclei.  (E and F) Absence of 
SRY staining (E) in the gonad 
of a female embryo. Shown in 
Fis the corresponding Hoechst 
staining.  Bars,  10/~m. 
tions and has not concentrated on tissues outside of the geni- 
tal ridge area, it is too early to conclude if these staining pat- 
terns  reflect different concentrations  of p27SRY.  However, 
this observation of p27SRY expression outside of the genital 
ridge is consistent with previous observations that the RNA 
for  SRY  could  be  detected  in  a  variety  of foetal  tissues 
(Clepet et al.,  1993). 
Localization of the p27SRY Protein 
in Microinjected Cells 
To examine in more detail the mechanisms involved in the 
nuclear localization of  p27SRY protein, we used microinjec- 
tion experiments  in human adult fibroblasts (HS68),  a  lin- 
eage negative for p27SRY expression. 
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a constitutive nuclear localization. Plasmids encoding the full length SRY ORF (pJ3SRY) or a mutant unable to bind DNA (pJ3SRYmutYC) 
were injected into HS68 cells. After 12-15 h at 37°C, cells were fixed  and localization of the p27SRY protein determined by indirect im- 
munofluorescence with the anti-SRY antibody Y127.3. On immunofluorescence  micrographs are: (A) the localization of wild type p27SRY 
protein; (B) an inert marker antibody revealing the injected cells with the pJ3SRY construct; (C) phase contrast micrograph in order to 
appreciate the background of the antibody in non-injected cells; (D) the localization of mutant p27SRY mutYC protein, and (E) a marker 
antibody co-injected with the plasmic pJ3SRY mutYC. Bar, 5 #m. 
Experiments were carried out as follows. Asynchronously 
growing cells were microinjected into the nucleus with plas- 
mids encoding the full length p27SRY protein under regula- 
tion of  a strong eukaryotic promoter (SV-40).  Microinjection 
solutions also included an inert mouse antibody in order to 
subsequently visualize injected ceils.  Cells  were then al- 
lowed to grow at 37°C,  12 to  15 h,  before processing for 
immunofluorescence with Y127.3 antibody. Results are pre- 
sented  in  Fig.  5.  Microinjected cells,  identified with  the 
staining of a coinjected marker antibody (Fig. 5 B), show 
a bright homogeneous nuclear staining for p27SRY in human 
fibroblasts (Fig. 5 A). Such nuclear staining was not present 
in the surrounding non-injected cells (identified by phase 
contrast micrography; Fig.  5  C).  Cells microinjected with 
an antisense p27SRY coding sequence containing plasmid or 
with the empty plasmid alone had a staining pattern similar 
to the background (data not shown). 
We conclude that recombinant p27SRY protein contains 
all the intrinsic properties to be translocated to the nucleus 
when microinjected in cells that normally do not express it. 
Nuclear Retention of  p27SRY Protein Does Not 
Depend on Its DNA Binding Activity 
To investigate if the nuclear retention of p27SRY protein de- 
pends on its DNA binding capacity, a mutant form of this 
protein, unable to bind DNA (and based on the SRY gene 
sequence of a mutated XY female), was produced (Poulat et 
al.,  1993). In this case, a tyrosine residue was changed for 
a cysteine at the position 127 of the p27SRY protein, a re~i- 
due located in the COOH-terminal part of  the HMG domain. 
Using gel shift assays,  we have previously demonstrated that 
a complete loss of the DNA binding activity of the SRY gene 
product results from this mutation, at least in vitro. This mu- 
tation  was  reproduced  in  a  pJ3SRY  expression  vector 
(termed pJ3SRY-mutYC).  12-15 h after microinjection of the 
expression vector in  HS68  cells  and  subsequent  staining 
with Y127.3 antibody, the p27SRY-mutYC is clearly nuclear 
(Fig.  5  D,  p27SRY-mutYC  protein; panel E,  marker anti- 
body). If nuclear retention was a function of a DNA binding 
activity, some cytoplasmic staining should be detected; how- 
ever,  even  in  the  cells  that  strongly  expressed  p27SRY- 
mutYC, only nuclear staining could be detected. From these 
results, we can conclude that for p27SRY, retention in the nu- 
cleus and DNA binding activity of the protein are two inde- 
pendent functions. 
A  Nuclear Localization Signal Is Present in p27SRY 
HMG Box 
To  identify  the  nuclear  localization  signal  (NLS)  of the 
p27SRY protein more precisely, the intracellular distribution 
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Figure 6. Characteristics of the SRY-derived peptides. The origins 
of the various peptides derived from the SRY open reading frame 
used  in these  data and  their  nuclear  localization  obtained  after 
microinjection are specified. 
of SRY-derived peptides after microinjection into HS68 cells 
was analyzed. The SRYS0 peptide corresponds to the entire 
p27SRY HMG box and SRY64 to the same box lacking the 
first 16 amino acids (Fig.  6). 
The  human  cells  were  injected  in  the  cytoplasm with 
SRY80-coupled IgG or SRY64-coupled IgG, fixed 30 min 
later, and stained with an antibody raised against rabbit IgG. 
As shown in Fig. 7, if SRYg0-IgG poptide is translocated to 
the  nucleus  in  HS68  fibroblasts (Fig.  7  A,  SRYS-IgG; B, 
marker antibody), the SRY64-IgG remained trapped in the 
cytoplasm when the cells were fixed from 0 to 30 min after 
injection (Fig. 7 C, SRY64-IgG; D, marker antibody). It is 
worth noting that SRY64-IgG is still localized in the cyto- 
plasm 2 or 3 h after microinjection (data not shown). These 
observations suggest that nuclear transport of SRY80 results 
Figure 7. Peptides derived from the putative DNA binding domain of human p27SRY show differential nuclear localization. Peptides from 
the DNA binding domain of human p27SRY were coupled to rabbit IgG. After purification, peptide-protein  complexes were microinjected 
into the cytoplasm of HS68 cells. After 30 min cells were fixed and the localization of the rabbit IgG detected by indirect immunofluores- 
cence with anti-rabbit biotinylated and fluorescent strepavidin. Shown are immunofluorescence micmgraphs revealing the localization of 
the injected peptides. (A) SRY80 peptide coupled to rabbit IgG; (C) SRY64 peptide coupled to rabbit IgG; (B and D) Inert marker antibody 
used to identifY the injected cells.  Bar, 5/zm. 
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box.  Assuming  that  nuclear translocation of p27SRY  was 
carried out by the usual pathway, we analyzed the amino acid 
sequence of p27SRY and found a bipartite NLS in the NHz- 
terminal part of the HMG box. Briefly, two basic domains 
separated by  12 amino acids (6~KRxxxxxxxxxRxxRRT~K), 
as first described for nucleoplasmin (Dingwall et al.,  1988; 
Dingwall and Laskey,  1991) were delineated in this part of 
the protein. This putative NLS present in the NH2-terminal 
of the HMG box of p27SRY must be deleted in the case of 
the truncated SRY64  peptide. 
Microinjection of  Peptides Reproducing the Putative 
p27SRY Nuclear Localization Signal 
To confirm the  role of a  putative NLS,  a  21-amino acid 
peptide (Fig. 6) corresponding to the NH2-terminal part of 
the  p27SRY  HMG  box  was  synthesized  and  coupled  to 
rabbit  IgG  (SRY21-IgG).  As  for SRY80-IgG and  SRY64- 
IgG, SRY21-IgG was injected in the cytoplasm of HS68 cells 
and processed for immunofluorescence (see Materials and 
Methods). Furthermore, the SRY17 peptide derived from the 
NH2-terminal part of full-length p27SRY protein  (Fig.  6) 
and carrying no putative nuclear localization sequence was 
coupled to rabbit IgG (SRY17-IgG)  and used as a  negative 
control. Finally, as a positive control, we produced an IgG- 
coupled peptide reproducing the strong nuclear localization 
signal from SV-40 large T  antigen (Dingwall et al.,  1991). 
As shown  in Fig.  8  (A and B),  this  SRY derived peptide 
SRY21 is able to drive rabbit IgG to the nucleus by itself, 
in the same way as the SV-40 NLS peptide (Fig. 8, E and F). 
On the contrary, the SRY17 peptide is inefficient for such a 
function (Fig. 8, C and D). Finally, in cells directly injected 
with rabbit IgG, only cytoplasmic staining can be detected 
(data not shown). 
We can conclude from these experiments that the NH2- 
terminal region of the DNA binding domain of p27SRY con- 
tains NLS. 
Mutational Analysis of the p27SRY NLS 
To further investigate the importance of the p27SRY NLS, 
we examined the subcellular localization of the full-length 
protein  deleted  of the  20  first  amino  acids  in  its  HMG 
domain. 
Deletion of amino acids 58Asp to 78Met was performed in 
pJ3SRY  expression vector (termed pJ3SRYANLS)  as  de- 
scribed in  Materials and Methods.  HS68 cells were fixed 
12-15  h  after  microinjection  of  the  resulting  plasmid. 
Anti-p27SRY staining revealed a bright immunoreactivity of 
Figure 8. Peptide from the pu- 
tative nuclear localization sig- 
nal  of  p27SRY specifically 
translocates proteins into the 
nucleus. A 21-amino acid pep- 
tide (SRY21)  corresponding to 
the NH2 terminus of the HMG 
domain of SRY, a peptide of 
17  amino acids  (SRY17) de- 
rived from the NH2 terminus 
domain of p27SRY and a pep- 
tide  reproducing  the  strong 
NLS  of the  large  T  antigen 
from SV-40 were coupled to 
rabbit IgG. After purification 
peptide  protein  complexes 
were  microinjected  into  the 
cytoplasm  of  human  fibro- 
blasts (HS68). 30 min there- 
after, cells were fixed, and the 
localization  of  the  peptide- 
rabbit  IgG detected by fluo- 
rescence  with  anti-rabbit 
biotinylated  and  fluorescent 
streptavidin. Shown are fluo- 
rescence micrographs reveal- 
ing  the  localization  of  the 
injected  peptide  rabbit  IgG 
complexes (A,  C, and E) or 
the marker antibody to show 
the  injected cells (B, D, and 
F).  (A and B) Cells injected 
with  SRY21-rabbit IgG. (C 
and  D)  Cells  injected  with 
SRY17-rabbit IgG. (E and F) 
Cells  injected  with  SV-40 
NLS-rabbit IgG. Bar, 5/zm. 
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is controlled by the first 20 amino acids of the HMG domain 
(Fig. 9 A, p27SRYANLS staining; B, marker antibody). In 
cells harboring a strong expression of p27SRYANLS, a little 
nuclear staining was also observed (data not shown). To hy- 
potheses can be made: first, another NLS of lower efficiency 
is present elsewhere in the p27SRY protein.  Second,  con- 
sidering that the SRY gene product is a relatively small pro- 
tein  (27  kD),  it  is  not  surprising  to  observe  a  passive 
diffusion of the NLS deleted protein into the nucleus across 
nucleopores (Peters,  1984,  1986).  This diffusion was con- 
firmed by the use of wild type p27SRY and p27SRYANLS 
fused to the/3-galactosidase gene in a pCHll0 plasmid (an 
SV-40  expression  vector  containing  the  /3-galactosidase 
gene). After microinjection and immunofluorescence detec- 
tion with the  Y127.3  antibody,  the p27SRYANLS-~-galac- 
tosidase fusion protein was only localized in the cytoplasm, 
in contrast with p27SRY-B-galactosidase which was nuclear 
(data not shown). 
Only  mutation  of both  basic  clusters  can  distinguish  a 
bipartite NLS from a  SV-40 prototype, i.e.,  a monopartite 
NLS.  To complete these data,  the two basic clusters were 
mutagenized independently to show their interdependence. 
In  the  first  mutant  (termed  pJ3SRYNLM1),  amino  acids 
6tLys-62Arg  were  changed  for Ser-Leu.  In the  second one 
(termed  pJ3SRYNLM2),  amino  acids  75Arg-76Arg  were 
changed for Leu-Leu.  Each expression vector was injected 
into HS68 growing cells as described before. As shown in 
Fig. 9 (C, p27SRYNLM1  staining; D, marker antibody; E, 
p27SRYNLM2 staining; F, marker antibody), the two mu- 
tant proteins display nuclear transport dramatically reduced 
or  even completely abolished.  Taken together,  these  data 
suggest that the p27SRY NLS requires both basic motifs in 
their integrity to allow the nuclear transport of the p27SRY 
protein.  To  conclude,  these  results  are  consistent  with 
p27SRY protein nuclear localization under control of a single 
bipartite NLS located in the NH2-terminal part of the HMG 
domain. 
Discussion 
To gain insights into the mode of action of the human sex de- 
termining protein p27SRY,  we have analysed its subcellular 
localization in mammalian cells using Western immunoblot- 
Figure  9.  p27SRY  nuclear 
transport is abolished by dele- 
tion and mutation of the NLS 
present  in  the  NH2-tenninal 
part of the HMG domain. Plas- 
mids encoding either a deleted 
NLS or mutated  form of the 
p27SRY protein were injected 
into HS68 cells. After 12-15 h 
at 37°C, cells were fixed and 
localization of the p27SRY pro- 
tein  determined  by  indirect 
immunofluorescence with the 
anti-SRY  antibody  Y127.3. 
Immunofluorescence  micro- 
graphs show: (A) the localiza- 
tion of p27SRYANLS protein 
arboring  a deletion  of amino 
acids 5SAsp to 7SMet, (B) in- 
ert marker antibody to reveal 
the injected cells with plasmid 
pJ3SRYANLS, (C) the local- 
ization  of  mutant  p27SRY 
NLM1  where  amino  acids 
6tLys-62Arg were changed for 
Ser-Leu, (D) marker antibody 
co-injected  with  the  plasmid 
pJ3SRY NLM1, (E) the local- 
ization  of  mutant  p27SRY 
NLM2.  Where  amino  acids 
75Arg-76Arg were changed for 
Leu-Leu, and (F) marker anti- 
body co-injected with the plas- 
mid  pJ3SRY NLM2.  Bar, 
5 btm. 
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with the help of a specific antibody. Expression of endoge- 
nous  p27SRY  in two different cell lines,  NT2D1  and  H8 
along  with  a  punctated  nuclear  localization  of the  pro- 
tein are clearly demonstrated. This localization was further 
characterized following microinjection experiments, reveal- 
ing the presence of a  bipartite basic  motif present in the 
p27SRY DNA binding domain and able to induce a nuclear 
localization for this protein. Interestingly, this motif appears 
highly conserved throughout the SOX protein family and in 
many HMG box containing proteins and thus could repre- 
sent the nuclear localization signal of many DNA binding 
proteins of this family (Table I) (Griess et al.,  1993). 
Immunoblotting,  indirect  immu'nofluorescence, and  ec- 
topic expression of p27SRY protein confirm that p27SRY is 
exclusively nuclear. From our data, it is also clear that this 
nuclear  localization  is  independent of the  p27SRY  DNA 
binding activity. The localization as the result of the random 
diffusion of p27SRY into the nucleus followed by its trapping 
via DNA binding was also dismissed.  As a matter of fact, 
we show that a small peptide (SRY21), derived from p27SRY 
sequence and without any detectable DNA binding activity 
(data not shown),  was  sufficient to drive immunoglobulin 
into the nucleus.  Furthermore a mutated form of p27SRY 
lacking  DNA  binding  activity  (Poulat  et  al.,  1993)  was 
clearly localized in the nucleus. In conclusion, our results 
suggest that nuclear retention of p27SRY is not in connection 
with its DNA binding activity. 
Nuclear localization of p27SRY  in cells expressing this 
protein spontaneously differs from that of cells overexpress- 
ing the protein transiently. In NT2DI or H8 cells as well as 
in  fetal gonadal  tissue,  the protein localizes to a  discrete 
number of immunofluorescent foci throughout the nucleus. 
In contrast, microinjected cells that overexpress the p27SRY 
protein show bright homogenous staining throughout the nu- 
cleus. The same result is obtained when NT2D1 or H8.2 cells 
are microinjected with the pJ3SRY expression vector (data 
not shown). It is clear that microinjected cells contain many 
copies of the expression vector, hence, drowning with the 
p27SRY protein, resulting in homogeneous staining.  How- 
ever, in stably transfected HeLa cells with the pJ3SRY ex- 
pression vector, nuclear staining is homogeneous and cannot 
be compared with p27SRY staining observed in NT2D1  or 
H8.2 cells. Thus, p27SRY could require a particular cellular 
environment to  display  punctated pattern  as  observed  in 
NT2D1 or H8.2 cells. This precise localization could repre- 
sent the binding of  p27SRY to specific DNA target sequences 
within the nucleus. The p27SRY protein has been shown to 
bind to the DNA in a sequence specific manner using small 
target sequences such as AACAAAG (Harley et al., 1991) or 
AACAAT (Denny et al.,  1992).  These small DNA motifs 
must be present in a high copy number in the human genome. 
However, since only 40 to 100 immunofluorescence foci are 
revealed with the Y127.3 antibody, criteria other than intrin- 
sic DNA binding specificity must be taken into account for 
this p27SRY protein localization. One of them could be an 
association of the p27SRY protein with other transcription 
factors, themselves interacting with their own DNA target 
sequences, as recently suggested for the HMG box contain- 
ing protein termed LEF1 (Giese and Grosschedl, 1993). Fur- 
thermore, the specificity of p27SRY DNA binding could be 
increased by interaction with a species specific protein com- 
plex, as determined for another HMG domain containing 
protein, UBF (Bell et al.,  1990). 
p27SRY nuclear localization requires a single nuclear lo- 
calization  signal  present  in  the  NH2-terminal  part  of the 
HMG domain.  For many transcription factors, the NLS is 
associated with the DNA binding domain (for example the 
glucocorticiod receptor; Hard et al.,  1990).  Indeed, most 
frequently nuclear localization signals contain several basic 
residues, which could be located in the region directly in- 
volved in DNA binding.  Moreover, rapid evolution of the 
SRY gene sequence out of the DNA binding motif in mam- 
mals  has  been  recently  reported  (Tucker and  Ludrigan, 
1993; Whitfield et al.,  1993). Thus, no homology between 
the NH2- and COOH-terminal domains (outside the HMG 
box) can be deduced from human  SRY  and mice Sry se- 
quences. The functional significance (if any) from these two 
domains remains puzzling. So, it is not surprising to find a 
nuclear localization signal belonging to the only conserved 
part of the SRY protein, a NLS highly conserved among all 
mammalian species in diverse proteins of the HMG family. 
To conclude, when first described (Sinclair et al.,  1990; 
Gubbay et al.,  1990), the SRY gene product was postulated 
to act as a transcriptional modulator. Since then, only two 
cellular properties have been clearly assigned to the p27SRY 
Table L  Comparison  of the Human p27SRY Nuclear Localization  Signal  with Putative Nuclear Localization  Signals of 
SOX and HMG Box Containing  Proteins 
Human SRY (Sinclair et al.,  1990) 
Mouse Sry Gubbay et al.,  1990) 
Rabbit SRY (Sinclair et al.,  1990) 
Dunnart (marsupial) SRY (Foster et al.,  1992) 
Gorilla SRY (Whitfield et al.,  1990) 
Mouse sox-I (Gubbay et al.,  1990) 
Mouse sox-2 (Gubbay et al.,  1990) 
Mouse sox-3 (Gubbay et al.,  1990) 
Mouse sox-4 (Gubbay et al.,  1990) 
Mouse sox-5 (Denny et al.,  1992) 
Human TCF-1 (Van de Wetering et al.,  1991) 
Rat IRE-ABP (Nasrin et al.,  1991) 
Human HMG1/2 (Wen et al.,  1989) 
Mouse LEF-I (Travis et al.,  1991) 

























Poulat et al. Nuclear Localization of the SRY Protein  747 protein: a well-documented DNA binding activity, and nu- 
clear localization, as shown precisely in this manuscript. In- 
terestingly, these two key functions are specified by the only 
conserved motif of the SRY gene throughout mammalian 
evolution: the HMG domain. 
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